Burixafor hydrobromide

Cat. No.: HY-19867A

CAS No.: 1191450-19-7

Molecular Formula: $C_{27}H_{51}N_8O_3P.5/_2HBr$

Molecular Weight: 769.01

Target: CXCR

Pathway: GPCR/G Protein; Immunology/Inflammation

Storage: -20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

H_2O : 50 mg/mL (65.02 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.3004 mL	6.5019 mL	13.0037 mL
	5 mM	0.2601 mL	1.3004 mL	2.6007 mL
	10 mM	0.1300 mL	0.6502 mL	1.3004 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
Solubility: 20 mg/mL (26.01 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well anti-angiogenic drug that is of potential value in treating choroid neovascularization[1]. Burixafor hydrobromide (TG-0054 hydrobromide) mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction[2].

IC_{50} & Target

CXCR4

REFERENCES

[1]. Shelke NB, et al. Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases. Drug Deliv Transl Res. 2011 Feb;1(1):76-90.

[2]. Hsu WT, et al. CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA